DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Public ClinicalTrials.gov record NCT03321513. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss. Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss
Study identification
- NCT ID
- NCT03321513
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2017 (Actual)
- Primary completion
- Dec 22, 2021 (Actual)
- Completion
- Dec 22, 2021 (Actual)
- Last update posted
- Oct 1, 2026
2017 – 2021
United States locations
- U.S. sites
- 54
- U.S. states
- 23
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Diagnostic Center | Campbell | California | 95008 | — |
| Macula & Retina Institute | Glendale | California | 91203 | — |
| Loma Linda University Health Care, Department of Ophthalmology | Loma Linda | California | 92354 | — |
| East Bay Retina Consultants, Inc | Oakland | California | 94609-3028 | — |
| National Ophthalmic Research Institute | Fort Myers | Florida | 33912 | — |
| Florida Retina Institute-Jacksonville | Jacksonville | Florida | 32216 | — |
| Florida Retina Consultants | Lakeland | Florida | 33805 | — |
| Retina Macula Specialists of Miami | Miami | Florida | 33126 | — |
| Central Florida Retina | Orlando | Florida | 32806 | — |
| Florida Retina Institute | Orlando | Florida | 32806 | — |
| Southeast Eye Institute, P.A. dba Eye Associates of Pinellas | Pinellas Park | Florida | 33782 | — |
| Fort Lauderdale Eye Institute | Plantation | Florida | 33324 | — |
| Retina Associates of Sarasota | Sarasota | Florida | 34233 | — |
| Sarasota Retina Institute | Sarasota | Florida | 34239 | — |
| Retina Associates of Florida, LLC | Tampa | Florida | 33609 | — |
| Retina Specialists of Tampa | Wesley Chapel | Florida | 33544 | — |
| Southeast Retina Center, P.C. | Augusta | Georgia | 30909 | — |
| Thomas Eye Group | Sandy Springs | Georgia | 30328 | — |
| Illinois Retina Associates, S.C. | Oak Park | Illinois | 60304 | — |
| Springfield Clinic, LLP | Springfield | Illinois | 62703 | — |
| Raj K. Maturi, M.D., P.C. | Indianapolis | Indiana | 46290 | — |
| John-Kenyon American Eye Institute | New Albany | Indiana | 47150 | — |
| Mid-America Retina Consultants, P.A. | Overland Park | Kansas | 66211 | — |
| Retina Associates, P.A. | Shawnee Mission | Kansas | 66204 | — |
| Paducah Retinal Center | Paducah | Kentucky | 42001 | — |
| Eye Associates of Northeast Louisiana dba Haik Humble Eye Center | West Monroe | Louisiana | 71291 | — |
| Mid Atlantic Retina Specialists | Hagerstown | Maryland | 21740 | — |
| Valley Eye Physicians and Surgeons | Ayer | Massachusetts | 01432 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| Retina Specialists of Michigan | Grand Rapids | Michigan | 49546 | — |
| Vitreo-Retinal Associates | Grand Rapids | Michigan | 49546 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Eye Associates of New Mexico | Albuquerque | New Mexico | 87109 | — |
| MaculaCare | New York | New York | 10021 | — |
| Retina Associates of Western New York | Rochester | New York | 14620 | — |
| Western Carolina Clinical Research, LLC | Asheville | North Carolina | 28803 | — |
| Charlotte Eye, Ear, Nose and Throat Assoc., PA | Charlotte | North Carolina | 28210 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Dean A. McGee Eye Institute | Oklahoma City | Oklahoma | 73104 | — |
| Retina Northwest, PC | Portland | Oregon | 97221 | — |
| Cascade Medical Research Institute, LLC | Springfield | Oregon | 97477 | — |
| Retina Vitreous Consultants | Monroeville | Pennsylvania | 15146 | — |
| Retinavitreous Associates, dba; Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107-5109 | — |
| Southeastern Retina Associates, P.C. | Knoxville | Tennessee | 37909 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
| Retina Research Center | Austin | Texas | 78705 | — |
| Retina Center of Texas | Grapevine | Texas | 76051 | — |
| Baylor Eye Physicians and Surgeons | Houston | Texas | 77030 | — |
| Retina Consultants of Houston, PA | Houston | Texas | 77030 | — |
| Texas Retina Associates | Lubbock | Texas | 79424 | — |
| Valley Retina Institute | McAllen | Texas | 78503 | — |
| Retinal Consultants of San Antonio | San Antonio | Texas | 78240 | — |
| Spokane Eye Clinic | Spokane | Washington | 99204 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03321513, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03321513 live on ClinicalTrials.gov.